These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Overcoming reprogramming resistance of Fanconi anemia cells. Müller LU; Milsom MD; Harris CE; Vyas R; Brumme KM; Parmar K; Moreau LA; Schambach A; Park IH; London WB; Strait K; Schlaeger T; Devine AL; Grassman E; D'Andrea A; Daley GQ; Williams DA Blood; 2012 Jun; 119(23):5449-57. PubMed ID: 22371882 [TBL] [Abstract][Full Text] [Related]
5. Generation of an induced pluripotent stem cell line that mimics the disease phenotypes from a patient with Fanconi anemia by conditional complementation. Bharathan SP; Nandy K; Palani D; Janet A NB; Natarajan K; George B; Srivastava A; Velayudhan SR Stem Cell Res; 2017 Apr; 20():54-57. PubMed ID: 28395741 [TBL] [Abstract][Full Text] [Related]
6. CRISPR/Cas9-Mediated Correction of the FANCD1 Gene in Primary Patient Cells. Skvarova Kramarzova K; Osborn MJ; Webber BR; DeFeo AP; McElroy AN; Kim CJ; Tolar J Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28613254 [TBL] [Abstract][Full Text] [Related]
7. Stem Cell Genetic Therapy for Fanconi Anemia - A New Hope. Hanenberg H; Roellecke K; Wiek C Curr Gene Ther; 2017; 16(5):309-320. PubMed ID: 28067166 [TBL] [Abstract][Full Text] [Related]
8. Pluripotent cell models of fanconi anemia identify the early pathological defect in human hemoangiogenic progenitors. Suzuki NM; Niwa A; Yabe M; Hira A; Okada C; Amano N; Watanabe A; Watanabe K; Heike T; Takata M; Nakahata T; Saito MK Stem Cells Transl Med; 2015 Apr; 4(4):333-8. PubMed ID: 25762002 [TBL] [Abstract][Full Text] [Related]
9. Naïve Induced Pluripotent Stem Cells Generated From β-Thalassemia Fibroblasts Allow Efficient Gene Correction With CRISPR/Cas9. Yang Y; Zhang X; Yi L; Hou Z; Chen J; Kou X; Zhao Y; Wang H; Sun XF; Jiang C; Wang Y; Gao S Stem Cells Transl Med; 2016 Jan; 5(1):8-19. PubMed ID: 26676643 [TBL] [Abstract][Full Text] [Related]
10. Effective CRISPR/Cas9-mediated correction of a Fanconi anemia defect by error-prone end joining or templated repair. van de Vrugt HJ; Harmsen T; Riepsaame J; Alexantya G; van Mil SE; de Vries Y; Bin Ali R; Huijbers IJ; Dorsman JC; Wolthuis RMF; Te Riele H Sci Rep; 2019 Jan; 9(1):768. PubMed ID: 30683899 [TBL] [Abstract][Full Text] [Related]
11. Brief report: human pluripotent stem cell models of fanconi anemia deficiency reveal an important role for fanconi anemia proteins in cellular reprogramming and survival of hematopoietic progenitors. Yung SK; Tilgner K; Ledran MH; Habibollah S; Neganova I; Singhapol C; Saretzki G; Stojkovic M; Armstrong L; Przyborski S; Lako M Stem Cells; 2013 May; 31(5):1022-9. PubMed ID: 23280624 [TBL] [Abstract][Full Text] [Related]
12. Advances in Gene Therapy for Fanconi Anemia. Río P; Navarro S; Bueren JA Hum Gene Ther; 2018 Oct; 29(10):1114-1123. PubMed ID: 30117331 [TBL] [Abstract][Full Text] [Related]
13. A protocol describing the genetic correction of somatic human cells and subsequent generation of iPS cells. Raya A; Rodríguez-Pizà I; Navarro S; Richaud-Patin Y; Guenechea G; Sánchez-Danés A; Consiglio A; Bueren J; Izpisúa Belmonte JC Nat Protoc; 2010 Apr; 5(4):647-60. PubMed ID: 20224565 [TBL] [Abstract][Full Text] [Related]
14. Gene Therapy in Fanconi Anemia: A Matter of Time, Safety and Gene Transfer Tool Efficiency. Verhoeyen E; Roman-Rodriguez FJ; Cosset FL; Levy C; Rio P Curr Gene Ther; 2017; 16(5):297-308. PubMed ID: 28067165 [TBL] [Abstract][Full Text] [Related]
15. Site-Specific Genome Engineering in Human Pluripotent Stem Cells. Merkert S; Martin U Int J Mol Sci; 2016 Jun; 17(7):. PubMed ID: 27347935 [TBL] [Abstract][Full Text] [Related]
16. Genome editing in pluripotent stem cells: research and therapeutic applications. Deleidi M; Yu C Biochem Biophys Res Commun; 2016 May; 473(3):665-74. PubMed ID: 26930470 [TBL] [Abstract][Full Text] [Related]
17. Gene correction in patient-specific iPSCs for therapy development and disease modeling. Jang YY; Ye Z Hum Genet; 2016 Sep; 135(9):1041-58. PubMed ID: 27256364 [TBL] [Abstract][Full Text] [Related]
18. Potential of Gene Editing and Induced Pluripotent Stem Cells (iPSCs) in Treatment of Retinal Diseases. Chuang K; Fields MA; Del Priore LV Yale J Biol Med; 2017 Dec; 90(4):635-642. PubMed ID: 29259527 [TBL] [Abstract][Full Text] [Related]
19. Induced pluripotent stem cells in research and therapy. Teoh HK; Cheong SK Malays J Pathol; 2012 Jun; 34(1):1-13. PubMed ID: 22870592 [TBL] [Abstract][Full Text] [Related]
20. The Combination of CRISPR/Cas9 and iPSC Technologies in the Gene Therapy of Human β-thalassemia in Mice. Ou Z; Niu X; He W; Chen Y; Song B; Xian Y; Fan D; Tang D; Sun X Sci Rep; 2016 Sep; 6():32463. PubMed ID: 27581487 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]